- Home
- WPP vs DNTH Comparison
WPP vs DNTH Comparison
Compare WPP & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WPP | DNTH |
|---|---|---|
| Founded | 1985 | 2015 |
| Country | United Kingdom | United States |
| Employees | 103277 | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 4.6B |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | WPP | DNTH |
|---|---|---|
| Price | $18.61 | $91.93 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 13 |
| Target Price | N/A | ★ $121.00 |
| AVG Volume (30 Days) | 385.0K | ★ 425.6K |
| Earning Date | 03-19-2026 | 05-06-2026 |
| Dividend Yield | ★ 11.68% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,036,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.32 | $29.48 |
| P/E Ratio | $38.96 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $14.81 | $16.77 |
| 52 Week High | $39.74 | $96.50 |
Technical Indicators
Market Signals| Indicator | WPP | DNTH |
|---|---|---|
| Relative Strength Index (RSI) | 58.65 | 59.23 |
| Support Level | $18.41 | $81.16 |
| Resistance Level | $19.08 | $96.50 |
| Average True Range (ATR) | 0.54 | 4.45 |
| MACD | 0.03 | 0.25 |
| Stochastic Oscillator | 78.04 | 85.05 |
Price Performance
Historical ComparisonAbout WPP WPP plc
Headquartered in the United Kingdom, WPP is the world's largest ad holding company based on annual revenue. Its services, which include traditional and digital advertising, public relations, and consulting, are provided worldwide, with over 70% of its revenue coming from more developed regions such as North America, the UK, and Western Europe. WPP is the largest media buying entity in the world.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.